$CCCC
C4 Therapeutics, Inc. Stock $cccc

$cccc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024006144 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$3.039M	$3.261M	$20.76M
YoY Change	-19.15%	14.26%	-33.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.29M	$10.30M	$42.08M
YoY Change	-6.0%	-1.89%	-1.65%
% of Gross Profit
Research & Development	$22.53M	$30.39M	$117.7M
YoY Change	-22.41%	-0.85%	-0.11%
% of Gross Profit
Depreciation & Amortization	$400.0K	$430.0K	$1.578M
YoY Change	-20.0%	-17.47%	-5.85%
% of Gross Profit
Operating Expenses	$35.26M	$40.69M	$159.8M
YoY Change	-11.83%	-1.12%	-0.52%
Operating Profit	-$32.22M		-$139.0M
YoY Change	-11.07%		7.33%
Interest Expense	$3.858M	$2.950M	$8.439M
YoY Change	166.44%	166.25%	520.97%
% of Operating Profit
Other Income/Expense, Net	$3.858M		$7.818M
YoY Change	166.44%		475.28%
Pretax Income	-$28.36M	-$34.48M	-$131.2M
YoY Change	-18.46%	-7.28%	2.37%
Income Tax	$0.00	$277.0K	$1.280M
% Of Pretax Income
Net Earnings	-$28.36M	-$34.75M	-$132.5M
YoY Change	-18.46%	-6.54%	3.37%
Net Earnings / Revenue	-933.23%	-1065.75%	-638.34%
Basic Earnings Per Share	-$0.41		-$2.67
Diluted Earnings Per Share	-$0.41	-$0.68	-$2.67
COMMON SHARES
Basic Shares Outstanding	68.60M shares	49.28M shares	49.64M shares
Diluted Shares Outstanding	68.43M shares		49.64M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$258.2M	$253.7M	$253.7M
YoY Change	-4.49%	-8.14%	-8.14%
Cash & Equivalents	$89.66M	$126.6M	$126.6M
Short-Term Investments	$168.5M	$127.1M	$127.1M
Other Short-Term Assets	$7.801M	$5.709M	$5.709M
YoY Change	2.66%	-42.51%	-42.51%
Inventory
Prepaid Expenses
Receivables	$13.60M	$11.80M	$11.80M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$279.6M	$271.2M	$271.2M
YoY Change	0.41%	-5.69%	-5.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.756M	$7.132M	$71.09M
YoY Change	-11.57%	-3.62%	-8.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$40.98M	$28.01M	$28.01M
YoY Change	18.06%	-54.06%	-54.06%
Other Assets	$5.228M	$2.723M	$6.166M
YoY Change	55.6%	78.44%	28.32%
Total Long-Term Assets	$118.8M	$105.3M	$105.3M
YoY Change	1.02%	-26.54%	-26.54%
TOTAL ASSETS
Total Short-Term Assets	$279.6M	$271.2M	$271.2M
Total Long-Term Assets	$118.8M	$105.3M	$105.3M
Total Assets	$398.4M	$376.5M	$376.5M
YoY Change	0.59%	-12.62%	-12.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.630M	$1.446M	$1.446M
YoY Change	57.64%	23.38%	23.38%
Accrued Expenses	$16.10M	$23.81M	$23.81M
YoY Change	-18.93%	6.2%	6.2%
Deferred Revenue	$35.14M	$15.47M
YoY Change	135.27%	-6.9%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$55.02M	$42.77M	$42.77M
YoY Change	39.71%	-4.0%	-4.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$85.07M	$87.57M	$87.57M
YoY Change	-0.58%	-0.33%	-0.33%
Total Long-Term Liabilities	$85.07M	$0.00	$87.57M
YoY Change	886.79%	-100.0%	-9.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$55.02M	$42.77M	$42.77M
Total Long-Term Liabilities	$85.07M	$0.00	$87.57M
Total Liabilities	$140.1M	$130.3M	$130.3M
YoY Change	4.88%	-7.96%	-7.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$556.7M	-$528.4M
YoY Change	29.25%	33.47%
Common Stock	$815.4M	$774.6M
YoY Change	17.22%	12.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$258.3M	$246.1M	$246.1M
YoY Change
Total Liabilities & Shareholders Equity	$398.4M	$376.5M	$376.5M
YoY Change	0.59%	-12.62%	-12.62%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$28.36M	-$34.75M	-$132.5M
YoY Change	-18.46%	-6.54%	3.37%
Depreciation, Depletion And Amortization	$400.0K	$430.0K	$1.578M
YoY Change	-20.0%	-17.47%	-5.85%
Cash From Operating Activities	-$18.12M	-$24.01M	-$106.8M
YoY Change	-45.3%	-17.57%	0.85%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$157.0K	$1.708M
YoY Change	-100.0%	-89.46%	-68.92%
Acquisitions
YoY Change
Other Investing Activities	-$53.40M	$32.10M	$160.1M
YoY Change	-198.66%	197.96%	150.41%
Cash From Investing Activities	-$53.40M	$31.94M	$158.3M
YoY Change	-199.75%	244.09%	171.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$57.56M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$34.58M	57.67M	$45.49M
YoY Change	-5155.99%	122606.38%	3865.91%
NET CHANGE
Cash From Operating Activities	-$18.12M	-24.01M	-$106.8M
Cash From Investing Activities	-$53.40M	31.94M	$158.3M
Cash From Financing Activities	$34.58M	57.67M	$45.49M
Net Change In Cash	-$36.93M	65.61M	$97.00M
YoY Change	-287.26%	-431.4%	-309.19%
FREE CASH FLOW
Cash From Operating Activities	-$18.12M	-$24.01M	-$106.8M
Capital Expenditures	$0.00	$157.0K	$1.708M
Free Cash Flow	-$18.12M	-$24.17M	-$108.5M
YoY Change	-46.26%	-21.07%	-2.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128175000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4141000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	307361000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001662579
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#CollaborativeArrangementMember
CY2023	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#CollaborativeArrangementMember
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39567
CY2023	dei	Entity Registrant Name EntityRegistrantName	C4 Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5617627
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	490 Arsenal Way
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 120
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	231-0700
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	CCCC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	129573953	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68600669	shares
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, MA, United States
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126590000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29754000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	127091000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	246399000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11799000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1473000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5709000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9931000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	271189000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	287557000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	28008000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	60962000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7132000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7400000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63956000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70116000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3443000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3279000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2723000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1526000	usd
CY2023Q4	us-gaap	Assets Assets	376451000	usd
CY2022Q4	us-gaap	Assets Assets	430840000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1446000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1172000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	20630000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	19769000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15471000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16618000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5219000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4700000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2287000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	42766000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44546000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	21814000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16895000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65757000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	70970000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9195000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	130337000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	141606000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60467188	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60467188	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48966216	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48966216	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	774618000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	689256000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-127000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4137000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-528383000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-395890000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	246114000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	289234000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	376451000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	430840000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20756000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31096000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	117706000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	117841000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42081000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42789000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	160630000	usd
CY2023	cccc	Interest Expense And Amortization Long Term Debt Related Party InterestExpenseAndAmortizationLongTermDebtRelatedParty	1373000	usd
CY2022	cccc	Interest Expense And Amortization Long Term Debt Related Party InterestExpenseAndAmortizationLongTermDebtRelatedParty	2216000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-621000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	9812000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7818000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1359000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-131213000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-128175000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1280000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-132493000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.67
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49640505	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49640505	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48861665	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48861665	shares
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	4010000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3362000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-128483000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-131537000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	389606000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	777000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	372000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29858000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3362000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128175000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	158000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	289234000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	57673000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4010000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-132493000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128175000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1880000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1676000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-621000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	77000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10327000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4244000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2723000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-388000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	273000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3333000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1316000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5083000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4695000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-507000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3772000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-22654000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106838000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-105939000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	289955000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	283445000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	129898000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	219527000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1708000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5496000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	158349000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58422000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	57673000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	12500000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	58000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	777000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	110000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	cccc	Aggregate Exercise Price Of Warrant Net Exercised Related Party AggregateExercisePriceOfWarrantNetExercisedRelatedParty	10000000	usd
CY2022	cccc	Aggregate Exercise Price Of Warrant Net Exercised Related Party AggregateExercisePriceOfWarrantNetExercisedRelatedParty	0	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	1003000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	473000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	44067000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-132500000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-528400000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	281700000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div>The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Areas where management uses subjective judgement include, but are not limited to, amounts and timing of revenues recognized under the Company’s research and development collaboration arrangements, prepaid and accrued research and development expense, estimates of the useful lives of long-lived assets, assessments of the impairment of long-lived assets, measurement of right-of-use assets and lease liabilities, incremental borrowing rate used in the measurement of lease liability, and valuation and recognition of share-based compensation expense. The Company assesses estimates on an ongoing basis, and bases its estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgements about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. Additionally, the Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</span></div>
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	281223000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	336865000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	155226000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	151000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	278000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	155099000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	311498000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	94	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	108594000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	278000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	120	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	289434000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	4141000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14895000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15523000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7763000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8123000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7132000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7400000	usd
CY2023	us-gaap	Depreciation Depreciation	1578000	usd
CY2022	us-gaap	Depreciation Depreciation	1676000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	10030000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	10031000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	1979000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	2026000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	2577000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	1481000	usd
CY2023	us-gaap	Lease Cost LeaseCost	9432000	usd
CY2022	us-gaap	Lease Cost LeaseCost	10576000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8828000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9093000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9366000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9646000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	11362000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	40751000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	89046000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18070000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	70976000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	33513000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16618000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16895000	usd
CY2023Q4	cccc	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	11243000	usd
CY2022Q4	cccc	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	9824000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	7344000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	6831000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2043000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3114000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	20630000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	19769000	usd
CY2023Q4	cccc	Accrued Research And Development Wind Down Activities AccruedResearchAndDevelopmentWindDownActivities	3100000	usd
CY2018Q4	cccc	Number Of Performance Obligations NumberOfPerformanceObligations	12	performanceobligation
CY2023Q4	cccc	Transaction Price Allocated To Performance Obligation TransactionPriceAllocatedToPerformanceObligation	67906000	usd
CY2023Q4	cccc	Transaction Price Unsatisfied To Performance Obligation TransactionPriceUnsatisfiedToPerformanceObligation	19064000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20756000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31096000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	11799000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15471000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	21814000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	37285000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1473000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	20185000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	25412000	usd
CY2023	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	43000	usd
CY2022	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	518000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1018000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	11482000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2287000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9195000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-600000	usd
CY2023	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	1000000	usd
CY2022	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	1500000	usd
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	cccc	Common Stock Number Of Votes Each Share CommonStockNumberOfVotesEachShare	1	vote
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27235000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30016000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.267
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.010
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1200000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.010
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.028
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.030
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.272
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	76000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1204000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1280000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1280000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.042
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.080
CY2023	cccc	Effective Income Tax Rate Reconciliation Federal Tax Credit EffectiveIncomeTaxRateReconciliationFederalTaxCredit	0.035
CY2022	cccc	Effective Income Tax Rate Reconciliation Federal Tax Credit EffectiveIncomeTaxRateReconciliationFederalTaxCredit	0.014
CY2023	cccc	Effective Income Tax Rate Reconciliation State Tax Credit EffectiveIncomeTaxRateReconciliationStateTaxCredit	0.014
CY2022	cccc	Effective Income Tax Rate Reconciliation State Tax Credit EffectiveIncomeTaxRateReconciliationStateTaxCredit	0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.008
CY2023	cccc	Effective Income Tax Rate Reconciliation Withholding Tax EffectiveIncomeTaxRateReconciliationWithholdingTax	-0.009
CY2022	cccc	Effective Income Tax Rate Reconciliation Withholding Tax EffectiveIncomeTaxRateReconciliationWithholdingTax	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	61036000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54300000	usd
CY2023Q4	cccc	Deferred Tax Assets Capitalized Research And Development Expenditures DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures	51401000	usd
CY2022Q4	cccc	Deferred Tax Assets Capitalized Research And Development Expenditures DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures	27568000	usd
CY2023Q4	cccc	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	20611000	usd
CY2022Q4	cccc	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	21443000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	18049000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	11519000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9061000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6296000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3881000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	8457000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	1204000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	0	usd
CY2023Q4	cccc	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	555000	usd
CY2022Q4	cccc	Deferred Tax Assets Capitalized Start Up Costs DeferredTaxAssetsCapitalizedStartUpCosts	699000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	1090000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	27000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	354000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	165825000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	131726000	usd
CY2023Q4	cccc	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	18573000	usd
CY2022Q4	cccc	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	19868000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1663000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1738000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	145589000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	110120000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	145600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	110100000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	35500000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	34700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	214900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	171600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	214900000	usd
CY2023	cccc	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActPercent	0.80
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	315300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	273600000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-132493000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-128175000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49640505	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49640505	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48861665	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48861665	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.67
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.03
CY2023	cccc	Defined Contribution Plan Employer Matching Contribution Additional Percent Of Employees Gross Pay DefinedContributionPlanEmployerMatchingContributionAdditionalPercentOfEmployeesGrossPay	0.50
CY2023	cccc	Defined Contribution Plan Employer Matching Contribution Additional Percent Of Match DefinedContributionPlanEmployerMatchingContributionAdditionalPercentOfMatch	0.05
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1000000	usd

Files In Submission

Name	View Source	Status
0001628280-24-006144-index-headers.html	Edgar Link	pending
0001628280-24-006144-index.html	Edgar Link	pending
0001628280-24-006144.txt	Edgar Link	pending
0001628280-24-006144-xbrl.zip	Edgar Link	pending
c4t-formofnsoagreementin.htm	Edgar Link	pending
c4t-formofnsoagreementin001.jpg	Edgar Link	pending
c4t-formofnsoagreementin002.jpg	Edgar Link	pending
c4t-formofnsoagreementin003.jpg	Edgar Link	pending
c4t-formofnsoagreementin004.jpg	Edgar Link	pending
c4t-formofnsoagreementin005.jpg	Edgar Link	pending
c4t-formofnsoagreementin006.jpg	Edgar Link	pending
cccc-20231231.htm	Edgar Link	pending
cccc-20231231.xsd	Edgar Link	pending
cccc-20231231x10kex311.htm	Edgar Link	pending
cccc-20231231x10kex312.htm	Edgar Link	pending
cccc-20231231x10kex321.htm	Edgar Link	pending
cccc-20231231x10kex322.htm	Edgar Link	pending
cccc-20231231_g1.jpg	Edgar Link	pending
cccc-20231231_g10.jpg	Edgar Link	pending
cccc-20231231_g11.jpg	Edgar Link	pending
cccc-20231231_g12.jpg	Edgar Link	pending
cccc-20231231_g13.jpg	Edgar Link	pending
cccc-20231231_g14.jpg	Edgar Link	pending
cccc-20231231_g15.jpg	Edgar Link	pending
cccc-20231231_g16.jpg	Edgar Link	pending
cccc-20231231_g17.jpg	Edgar Link	pending
cccc-20231231_g18.jpg	Edgar Link	pending
cccc-20231231_g2.jpg	Edgar Link	pending
cccc-20231231_g3.jpg	Edgar Link	pending
cccc-20231231_g4.jpg	Edgar Link	pending
cccc-20231231_g5.jpg	Edgar Link	pending
cccc-20231231_g6.jpg	Edgar Link	pending
cccc-20231231_g7.jpg	Edgar Link	pending
cccc-20231231_g8.jpg	Edgar Link	pending
cccc-20231231_def.xml	Edgar Link	unprocessable
cccc-20231231_g9.jpg	Edgar Link	pending
ex97-executivecompensati.htm	Edgar Link	pending
ex97-executivecompensati001.jpg	Edgar Link	pending
ex97-executivecompensati002.jpg	Edgar Link	pending
ex97-executivecompensati003.jpg	Edgar Link	pending
ex97-executivecompensati004.jpg	Edgar Link	pending
ex97-executivecompensati005.jpg	Edgar Link	pending
exhibit2112023.htm	Edgar Link	pending
exhibit2312023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
merck-c4txlicenseandcoll.htm	Edgar Link	pending
merck-c4txlicenseandcoll001.jpg	Edgar Link	pending
merck-c4txlicenseandcoll002.jpg	Edgar Link	pending
merck-c4txlicenseandcoll003.jpg	Edgar Link	pending
merck-c4txlicenseandcoll004.jpg	Edgar Link	pending
merck-c4txlicenseandcoll005.jpg	Edgar Link	pending
merck-c4txlicenseandcoll006.jpg	Edgar Link	pending
merck-c4txlicenseandcoll007.jpg	Edgar Link	pending
merck-c4txlicenseandcoll008.jpg	Edgar Link	pending
merck-c4txlicenseandcoll009.jpg	Edgar Link	pending
merck-c4txlicenseandcoll010.jpg	Edgar Link	pending
merck-c4txlicenseandcoll011.jpg	Edgar Link	pending
merck-c4txlicenseandcoll012.jpg	Edgar Link	pending
merck-c4txlicenseandcoll013.jpg	Edgar Link	pending
merck-c4txlicenseandcoll014.jpg	Edgar Link	pending
merck-c4txlicenseandcoll015.jpg	Edgar Link	pending
merck-c4txlicenseandcoll016.jpg	Edgar Link	pending
merck-c4txlicenseandcoll017.jpg	Edgar Link	pending
merck-c4txlicenseandcoll018.jpg	Edgar Link	pending
merck-c4txlicenseandcoll019.jpg	Edgar Link	pending
merck-c4txlicenseandcoll020.jpg	Edgar Link	pending
merck-c4txlicenseandcoll021.jpg	Edgar Link	pending
merck-c4txlicenseandcoll022.jpg	Edgar Link	pending
merck-c4txlicenseandcoll023.jpg	Edgar Link	pending
merck-c4txlicenseandcoll024.jpg	Edgar Link	pending
merck-c4txlicenseandcoll025.jpg	Edgar Link	pending
merck-c4txlicenseandcoll026.jpg	Edgar Link	pending
merck-c4txlicenseandcoll027.jpg	Edgar Link	pending
merck-c4txlicenseandcoll028.jpg	Edgar Link	pending
merck-c4txlicenseandcoll029.jpg	Edgar Link	pending
merck-c4txlicenseandcoll030.jpg	Edgar Link	pending
merck-c4txlicenseandcoll031.jpg	Edgar Link	pending
merck-c4txlicenseandcoll032.jpg	Edgar Link	pending
merck-c4txlicenseandcoll033.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
cccc-20231231_htm.xml	Edgar Link	completed
merck-c4txlicenseandcoll034.jpg	Edgar Link	pending
merck-c4txlicenseandcoll035.jpg	Edgar Link	pending
merck-c4txlicenseandcoll036.jpg	Edgar Link	pending
merck-c4txlicenseandcoll037.jpg	Edgar Link	pending
merck-c4txlicenseandcoll038.jpg	Edgar Link	pending
merck-c4txlicenseandcoll039.jpg	Edgar Link	pending
merck-c4txlicenseandcoll040.jpg	Edgar Link	pending
merck-c4txlicenseandcoll041.jpg	Edgar Link	pending
merck-c4txlicenseandcoll042.jpg	Edgar Link	pending
merck-c4txlicenseandcoll043.jpg	Edgar Link	pending
merck-c4txlicenseandcoll044.jpg	Edgar Link	pending
merck-c4txlicenseandcoll045.jpg	Edgar Link	pending
merck-c4txlicenseandcoll046.jpg	Edgar Link	pending
merck-c4txlicenseandcoll047.jpg	Edgar Link	pending
merck-c4txlicenseandcoll048.jpg	Edgar Link	pending
merck-c4txlicenseandcoll049.jpg	Edgar Link	pending
merck-c4txlicenseandcoll050.jpg	Edgar Link	pending
merck-c4txlicenseandcoll051.jpg	Edgar Link	pending
merck-c4txlicenseandcoll052.jpg	Edgar Link	pending
merck-c4txlicenseandcoll053.jpg	Edgar Link	pending
merck-c4txlicenseandcoll054.jpg	Edgar Link	pending
merck-c4txlicenseandcoll055.jpg	Edgar Link	pending
merck-c4txlicenseandcoll056.jpg	Edgar Link	pending
merck-c4txlicenseandcoll057.jpg	Edgar Link	pending
merck-c4txlicenseandcoll058.jpg	Edgar Link	pending
merck-c4txlicenseandcoll059.jpg	Edgar Link	pending
merck-c4txlicenseandcoll060.jpg	Edgar Link	pending
merck-c4txlicenseandcoll061.jpg	Edgar Link	pending
merck-c4txlicenseandcoll062.jpg	Edgar Link	pending
merck-c4txlicenseandcoll063.jpg	Edgar Link	pending
merck-c4txlicenseandcoll064.jpg	Edgar Link	pending
merck-c4txlicenseandcoll065.jpg	Edgar Link	pending
merck-c4txlicenseandcoll066.jpg	Edgar Link	pending
merck-c4txlicenseandcoll067.jpg	Edgar Link	pending
merck-c4txlicenseandcoll068.jpg	Edgar Link	pending
merck-c4txlicenseandcoll069.jpg	Edgar Link	pending
merck-c4txlicenseandcoll070.jpg	Edgar Link	pending
merck-c4txlicenseandcoll071.jpg	Edgar Link	pending
merck-c4txlicenseandcoll072.jpg	Edgar Link	pending
merck-c4txlicenseandcoll073.jpg	Edgar Link	pending
merck-c4txlicenseandcoll074.jpg	Edgar Link	pending
merck-c4txlicenseandcoll075.jpg	Edgar Link	pending
merck-c4txlicenseandcoll076.jpg	Edgar Link	pending
merck-c4txlicenseandcoll077.jpg	Edgar Link	pending
merck-c4txlicenseandcoll078.jpg	Edgar Link	pending
merck-c4txlicenseandcoll079.jpg	Edgar Link	pending
merck-c4txlicenseandcoll080.jpg	Edgar Link	pending
merck-c4txlicenseandcoll081.jpg	Edgar Link	pending
merck-c4txlicenseandcoll082.jpg	Edgar Link	pending
merck-c4txlicenseandcoll083.jpg	Edgar Link	pending
merck-c4txlicenseandcoll084.jpg	Edgar Link	pending
merck-c4txlicenseandcoll085.jpg	Edgar Link	pending
merck-c4txlicenseandcoll086.jpg	Edgar Link	pending
merck-c4txlicenseandcoll087.jpg	Edgar Link	pending
merck-c4txlicenseandcoll088.jpg	Edgar Link	pending
merck-c4txlicenseandcoll089.jpg	Edgar Link	pending
merck-c4txlicenseandcoll090.jpg	Edgar Link	pending
merck-c4txlicenseandcoll091.jpg	Edgar Link	pending
merck-c4txlicenseandcoll092.jpg	Edgar Link	pending
merck-c4txlicenseandcoll093.jpg	Edgar Link	pending
merck-c4txlicenseandcoll094.jpg	Edgar Link	pending
merck-c4txlicenseandcoll095.jpg	Edgar Link	pending
merck-c4txlicenseandcoll096.jpg	Edgar Link	pending
merck-c4txlicenseandcoll097.jpg	Edgar Link	pending
merck-c4txlicenseandcoll098.jpg	Edgar Link	pending
merck-c4txlicenseandcoll099.jpg	Edgar Link	pending
merck-c4txlicenseandcoll100.jpg	Edgar Link	pending
merck-c4txlicenseandcoll101.jpg	Edgar Link	pending
merck-c4txlicenseandcoll102.jpg	Edgar Link	pending
merck-c4txlicenseandcoll103.jpg	Edgar Link	pending
merck-c4txlicenseandcoll104.jpg	Edgar Link	pending
merck-c4txlicenseandcoll105.jpg	Edgar Link	pending
merck-c4txlicenseandcoll106.jpg	Edgar Link	pending
merck-c4txlicenseandcoll107.jpg	Edgar Link	pending
merck-c4txlicenseandcoll108.jpg	Edgar Link	pending
merck-c4txlicenseandcoll109.jpg	Edgar Link	pending
merck-c4txlicenseandcoll110.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cccc-20231231_lab.xml	Edgar Link	unprocessable
cccc-20231231_pre.xml	Edgar Link	unprocessable
cccc-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CCCC
C4 Therapeutics, Inc. Stock $cccc

2024 Q1 Form 10-K Financial Statement

#000162828024006144 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CCCC C4 Therapeutics, Inc. Stock $cccc

2024 Q1 Form 10-K Financial Statement

#000162828024006144 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CCCC
C4 Therapeutics, Inc. Stock $cccc